AZD 9829
Alternative Names: AZD-9829Latest Information Update: 17 Sep 2024
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 13 Jun 2024 Pharmacodynamics data from a preclinical studies in Acute myeloid leukaemia presented at the 29th Congress of the European Haematology Association, 2024 (EHA-2024)
- 31 Jan 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in South Korea (IV) (NCT06179511)
- 31 Jan 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT06179511)